imatinib mesylate has been researched along with kw 2449 in 1 studies
| Studies (imatinib mesylate) | Trials (imatinib mesylate) | Recent Studies (post-2010) (imatinib mesylate) | Studies (kw 2449) | Trials (kw 2449) | Recent Studies (post-2010) (kw 2449) |
|---|---|---|---|---|---|
| 11,477 | 960 | 5,773 | 23 | 0 | 20 |
| Protein | Taxonomy | imatinib mesylate (IC50) | kw 2449 (IC50) |
|---|---|---|---|
| Replicase polyprotein 1ab | Betacoronavirus England 1 | 3.6 | |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.009 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.0066 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Attkisson, E; Dai, Y; Grant, S; Jordan, N; Kolluri, N; Kramer, L; Muschen, M; Nguyen, N; Nguyen, T | 1 |
1 other study(ies) available for imatinib mesylate and kw 2449
| Article | Year |
|---|---|
HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, SCID; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Xenograft Model Antitumor Assays | 2011 |